Core Insights - Microbot Medical Inc. has received its first patent in Japan for the LIBERTY® Endovascular Robotic System, enhancing its intellectual property portfolio [1] - The U.S. FDA granted marketing clearance for the LIBERTY® System on September 8, 2025, prompting the company to accelerate its commercial launch plans targeting 2.5 million peripheral endovascular procedures annually in the U.S. [2] - The company is focusing on the U.S. market while exploring opportunities in other global markets, particularly Japan, which may expedite local approval and adoption of its technology [3] Company Overview - Microbot Medical Inc. is a medical device company specializing in advanced robotic technology aimed at transforming endovascular procedures [3] - The LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and provider safety [3] - The company is committed to innovation and has a strong intellectual property portfolio to support its growth [3]

Core Viewpoint - Microbot Medical Inc. (MBOT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2025, Microbot Medical is expected to earn -$0.30 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6.3% over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Microbot Medical in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Insights - Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System, marking a significant milestone for the company in the commercialization of this innovative medical device [2][3] - The CEO, Harel Gadot, will discuss the implications of this FDA clearance and the company's commercialization plans during a live interview on Benzinga All Access [1] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with the LIBERTY® Endovascular Robotic System being the first single-use, remotely operated robotic solution designed for precision and efficiency [3] - The company is backed by a strong intellectual property portfolio and is committed to innovation in the field of endovascular care [3]

Group 1 - Microbot Medical Inc. (NASDAQ:MBOT) has experienced a significant decline, with a 6.93% drop in share price, closing at $3.09, amid concerns over potential dilution from a fundraising program worth $63 million [1][4]. - The company raised $25.2 million from an options exercise, covering 12.06 million shares at prices between $1.5 and $2.13 [2]. - A second offering is expected to close on October 15, with over 1.9 million shares anticipated to be exercised at $2.10 each, potentially raising around $4 million [3]. Group 2 - The net proceeds from the fundraising efforts are intended for the development, commercialization, and regulatory activities of the LIBERTY Robotic System, as well as for potential acquisitions, expansion of applications from its existing IP portfolio, and general corporate purposes [5].

Core Viewpoint - Microbot Medical Inc. has successfully closed the first tranche of a preferred investment options offering, raising approximately $25.2 million, with a second tranche expected to yield an additional $4 million, and potential gross proceeds of up to $63 million from future exercises of short-term preferred investment options [1][4]. Group 1: Offering Details - The first closing involved the exercise of preferred investment options to purchase up to 12,064,627 shares of common stock at exercise prices ranging from $1.50 to $2.13 per share [2]. - The second closing is anticipated by October 15, 2025, and will involve the exercise of options for 1,924,488 shares at an exercise price of $2.10 per share, with new options issued at $4.50 per share [2][4]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated towards the development, commercialization, and regulatory activities for the LIBERTY Robotic System, potential acquisitions, and general corporate purposes [4]. Group 3: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY Endovascular Robotic System being the first single-use, remotely operated robotic solution designed for precision and efficiency [7].

Core Viewpoint - Microbot Medical Inc. has entered into definitive agreements to exercise preferred investment options, allowing the purchase of up to 13,989,115 shares of common stock, with the offering expected to close in two tranches [1][2]. Group 1: Offering Details - The first closing of the offering is anticipated on or about September 16, 2025, involving the exercise of options for 12,064,627 shares at prices between $1.50 and $2.13 per share [2]. - The second closing is expected by October 15, 2025, for 1,924,488 shares at an exercise price of $2.10 per share [2]. - New unregistered short-term series J preferred investment options will be issued in connection with the cash exercise of these options, with an exercise price of $4.50 per share [2]. Group 2: Financial Proceeds - Gross proceeds from the first closing are projected to be approximately $25.2 million, while the second closing is expected to yield around $4 million [4]. - If fully exercised, the new short-term series J preferred investment options could generate additional gross proceeds of approximately $63 million [4]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized for the development, commercialization, and regulatory activities of the LIBERTY® Robotic System, potential acquisitions, and general corporate purposes [4]. Group 4: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY® Endovascular Robotic System being a key product [8].

Company Overview - Microbot Medical Inc. (MBOT) received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a significant regulatory achievement for the company [1][4] - The LIBERTY system aims to enhance control and precision in endovascular procedures while minimizing radiation exposure and the use of contrast media [1][9] Market Position and Growth Potential - The FDA clearance positions Microbot for entry into the U.S. market, transforming years of research and development into a commercial opportunity [2][4] - The company is focusing on expanding its presence in the robotic surgery market, leveraging the LIBERTY system's compact and disposable design to differentiate from existing platforms [2][10] Stock Performance - Following the FDA announcement, MBOT shares increased by 22.9% at market close, with a year-to-date surge of 301.8%, contrasting with an 8.1% decline in the industry [3][8] - The current market capitalization of MBOT is $166.7 million, with projected earnings growth of 53.4% for the current year [5] Product Features and Clinical Data - The LIBERTY system is a fully disposable, remotely operated device that demonstrated 100% navigation success in trials, with a 92% relative reduction in radiation exposure for physicians [8][11] - The system's design aims to improve ergonomics, reduce physical strain on healthcare providers, and enhance procedural efficiency while lowering costs [11] Industry Outlook - The global surgical robot systems market is projected to grow from $11.48 billion in 2024 to $23.13 billion by 2030, with a CAGR of 12.4% from 2025 to 2030, driven by technological advancements and a preference for minimally invasive procedures [12]

Core Insights - Microbot Medical Inc. has received FDA clearance for its LIBERTY Endovascular Robotic System, marking it as the first single-use, remotely operated robotic system for peripheral endovascular procedures [1][2]. Company Overview - Microbot Medical Inc. is a medical device company focused on transforming endovascular procedures through advanced robotic technology [2]. - The LIBERTY Endovascular Robotic System is designed for precision, efficiency, and provider safety, supported by a strong intellectual property portfolio [2]. Event Announcement - Harel Gadot, CEO, President & Chairman of Microbot Medical, will present at the H.C. Wainwright Annual Investor Conference, highlighting the recent FDA clearance of the LIBERTY System [1]. - The presentation is scheduled for September 9 at 9:00am ET and will be available via a live webcast on the company's website [1].

Core Insights - Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a significant milestone for the company and the endovascular robotics field [3][4] - The company aims to commercialize the LIBERTY System in the U.S. by Q4 2025, targeting an addressable market of approximately 2.5 million peripheral endovascular procedures annually [2][4] - The LIBERTY System demonstrated a 100% success rate in robotic navigation to target and a 92% relative reduction in radiation exposure for physicians during its pivotal study [4] Company Developments - The CEO, Harel Gadot, emphasized that the FDA clearance validates the company's mission to enhance access to advanced robotic technologies and supports cost-effective healthcare [4] - The company has been developing its commercial readiness strategy since Q2 2025, positioning itself to accelerate market entry following FDA clearance [4] - Microbot Medical plans to continue collecting clinical data for the LIBERTY System during its commercial launch [4] Market Positioning - The LIBERTY System is the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures, aiming to transform the field by reducing the need for traditional capital equipment and dedicated infrastructure [3][4] - The remote design of the LIBERTY System is expected to improve ergonomics and reduce physical strain on healthcare providers, potentially enhancing procedure efficiency and lowering costs [4][6] - The company will present its developments at the H.C. Wainwright Annual Investor Conference on September 9, 2025, to engage with investors and stakeholders [5]

Core Insights - Microbot Medical Inc. (MBOT) has received a new U.S. patent that enhances the LIBERTY Endovascular Robotic System's applications, allowing for interchangeable tool-receiver units, thus broadening its use in endovascular procedures [1][8] - The new intellectual property (IP) is expected to increase the addressable market for the company from approximately 2.5 million to over six million annual endovascular procedures in the U.S., significantly expanding its market potential [2][8] - Following the patent announcement, MBOT's shares rose by 7.1%, with a year-to-date increase of 195.5%, contrasting with a 7% decline in the industry [3][7] Company Developments - The newly granted patent strengthens Microbot's long-term growth prospects by broadening the LIBERTY system's potential applications, enhancing its competitive differentiation and positioning for future partnerships and revenue opportunities once FDA clearance is obtained [4][8] - MBOT currently has a market capitalization of $140.7 million and projects an earnings growth of 56.2% for the current year [5] Product Overview - The LIBERTY system is designed as a single-use, fully disposable robotic platform for endovascular procedures, aimed at simplifying workflow and reducing risks associated with reprocessing [9][10] - Its modular architecture allows for configuration across various clinical applications, potentially increasing its relevance in a wider range of procedures than initially targeted [9][10]